The U.S. Department of Justice issued a news release regarding the case of Brian Parks and MedFitRX Inc. (now MedFit Sarmacuticals Inc.), in which Parks and his associates knowingly distributed several steroid-like drugs despite the fact that the Food and Drug Administration had not approved of those drugs:
Parks admitted that, from approximately June 2017 to September 2019, he and his company unlawfully distributed Selective Androgen Receptor Modulators (SARMs) and other substances that the FDA has not approved, including Ostarine (MK-2866), Ligandrol (LGD-4033), and Testolone (RAD-140). SARMs are synthetic chemicals designed to mimic the effects of testosterone and other anabolic steroids. The FDA has long warned against the use of SARMs like those found in MedFit products, including stating in a 2017 warning letter to another firm that SARMs have been linked to life-threatening reactions including liver toxicity, and have the potential to increase the risk of heart attack and stroke.
Sentencing is set for February 16, 2021.